Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRosana Kapeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
Estimating the term…
The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
An isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 nucleic acid molecule selected from the group consisting of:
An isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 polypeptide selected from the group consisting of:
A method for identifying a compound capable of treating a disorder characterized by aberrant 27875, 22025, 27420, 17906, 16319, 55092 or 10218 activity, comprising assaying the ability of the compound to modulate 27875, 22025, 27420, 17906, 16319, 55092 or 10218 nucleic acid expression or 27875, 22025, 27420, 17906, 16319, 55092 or 10218 polypeptide activity, thereby identifying a compound capable of treating a disorder characterized by aberrant 27875, 22025, 27420, 17906, 16319, 55092 or 10218 activity.
Dependencies are inferred from the claim text.